Triesence Approval History
FDA Approved: Yes (First approved November 29, 2007)
Brand name: Triesence
Generic name: triamcinolone acetonide
Dosage form: Injectable Suspension
Company: Alcon, Inc.
Treatment for: Temporal Arteritis, Uveitis
Triesence (triamcinolone acetonide) is a synthetic corticosteroid indicated for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Development History and FDA Approval Process for Triesence
|Dec 3, 2007||Alcon Receives FDA Approval of Triesence Injectable Triamcinolone Suspension for Use in Eye Surgery|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.